Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
In the last 90 days, Solid Biosciences Inc. insiders filed 0 open-market purchases and 1 sale; 157 institutions reported holding it in 13F filings for Q3 2026, worth $856.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $697.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $24.6K in total
- 1
- 13F holdersQ3 2026, +4 vs. previous quarter
- 157
- 13F valueReported value at the end of Q3 2026
- $856.6M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$174.3M
- No comparable prior period
- Free cash flow, FY2025
- -$157.4M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 13.3M
- Shares sold short
- Change
- +1.00M
- +8.2% vs. previous
- Days to cover
- 10.71
- At average daily volume
Superinvestors holding SLDB, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding SLDB at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Solid Biosciences Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2026 (view filing)4:05 PM ET | Oct 19 | 1 day | Brooks GabrielChief Medical Officer | SSale | −4.37K | $5.62 | −$24.6K | −4.3%97.2K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Cumbo AlexanderPresident and CEO | SSale | −16.6K | $5.82 | −$96.9K | −6.6%235.4K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Hanrahan JessieChief Regulatory Officer | SSale | −4.13K | $5.82 | −$24.1K | −5.3%74.3K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Ganot IlanDirector | SSale | −2.66K | $5.82 | −$15.5K | −8.8%27.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Herzich PaulChief Technology Officer | SSale | −3.62K | $5.82 | −$21.0K | −4.7%72.6K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Howton David TChief Operating Officer | SSale | −7.47K | $5.82 | −$43.5K | −6.6%105.1K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Brooks GabrielChief Medical Officer | SSale | 0 | – | $0 | 0.0%89.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Tan KevinCFO & Treasurer | SSale | −5.40K | $5.82 | −$31.5K | −5.2%99.4K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Howton David TChief Operating Officer | SSale | −18.9K | $6.44 | −$121.7K | −16.2%97.9K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Cumbo AlexanderPresident and CEO | SSale | −48.9K | $6.44 | −$315.0K | −18.1%222.0K after | 10b5-1 |
Top 10 13F holders, Q3 2026
See all 157 holdersThe largest institutional positions in Solid Biosciences Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,036,126 | $87.0M | 0.87% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 11,906,646 | $86.1M | 1.61% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 9,808,819 | $70.9M | 4.76% | 00.0% | Unchanged |
| Siren, L.L.C. | 7,690,405 | $55.6M | 1.32% | 00.0% | Unchanged |
| FMR LLC | 7,273,369 | $52.6M | 0.00% | +397,412+5.8% | Added |
| BlackRock, Inc. | 6,835,244 | $49.4M | 0.00% | −99,004−1.4% | Reduced |
| RTW Investments, LP | 5,905,426 | $42.7M | 0.43% | +2,012,500+51.7% | Added |
| Armistice Capital, LLC | 4,496,000 | $32.5M | 1.09% | +218,000+5.1% | Added |
| Vanguard Capital Management LLC | 3,967,899 | $28.7M | 0.00% | −42,023−1.0% | Reduced |
| Franklin Resources Inc | 4,193,497 | $27.3M | 0.01% | +752,789+21.9% | Added |
Holders of 5% or more of SLDB
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Solid Biosciences Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 13D/A | 11.20%12.0M shares | −1.70 ppfrom 12.90% | Mar 23, 20219 filings | Aug 14, 2026 | SEC |
| Ra Capital Management, L.P. | 13D/A | 10.80%12.0M shares | −1.10 ppfrom 11.90% | Mar 23, 202112 filings | Nov 6, 2026 | SEC |
| Invus Global Management, LLC | 13G/A | 9.99%10.1M shares | +0.39 ppfrom 9.60% | Aug 2, 20245 filings | May 5, 2026 | SEC |
| BCLS SB Investco, LP | 13D/A | 8.80%8.60M shares | +1.00 ppfrom 7.80% | Mar 25, 20219 filings | Mar 10, 2026 | SEC |
| FMR LLC | 13G | 7.00%6.88M shares | New | Aug 6, 20261 filing | Aug 6, 2026 | SEC |